OTCMKTS:TLTFF
Theralase Technologies Inc. Stock News
$0.124
+0.0021 (+1.73%)
At Close: May 20, 2024
Theralase is making personalized cancer treatment a reality
10:16am, Friday, 26'th Jan 2024
A new treatment for bladder cancer could offer a higher quality of life for patients for an extended period of time compared to existing therapies. Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF),
Theralase provides encouraging interim results for Phase II study on bladder cancer treatment
08:53am, Monday, 15'th Jan 2024
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) has released interim clinical data for its Phase II non-muscle invasive bladder cancer study indicating complete response rates exceeding Internatio
Theralase(R) Provides Update on Phase II Bladder Cancer Clinical Study
07:00am, Monday, 15'th Jan 2024
TORONTO, ON / ACCESSWIRE / January 15, 2024 / Theralase® Technologies Inc. (" Theralase® " or the " Company ") ( TSXV:TLT )( OTCQB:TLTFF ), a clinical stage pharmaceutical company dedicated to the r
Theralase Technologies CEO Roger DuMoulin-White talks Phase II clinical bladder cancer trial, progress with FDA
03:36pm, Friday, 15'th Dec 2023
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is developing a drug targeting non-muscle invasive bladder cancer that CEO Roger DuMoulin-White says has shown super data compared to two Big Pharma
Theralase focused on breakthrough designation after positive preliminary study data
12:33pm, Thursday, 30'th Nov 2023
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is aiming to leverage positive study data during 3Q into a Breakthrough Therapy designation from the US Food and Drug Administration. The clinical-s
Theralase at 52-Week Highs on Vaccine Developments
04:45pm, Monday, 07'th Feb 2022 Baystreet Canada
Theralase Technologies Inc. (V.TLT) hit a new 52-week high of 45.5 cents on Monday. Theralase has demonstrated proof-of-concept for the development of a Canadian-made SARS-CoV-2 vaccine. Atlas Engineered Products Ltd. (V.AEP) hit a new 52-week high of 66 cents on Monday. No news stories available today. Artis Real Estate Investment Trust (T.AX.UN) hit a new 52-week high of $12.45 on Monday. No news stories available today. Bri-Chem Corp. (T.BRY) hit a new 52-week high of 37 cents on Monday. No news stories available today. Colliers International Group Inc. (T.CIGI) hit a new 52-week high of $189.81 on Monday. No news stories available today. DREAM Unlimited Corp. (T.DRM) hit a new 52-week high of $41.39 on Monday. No news stories available today. Essential Energy Services Ltd. (T.ESN) hit a new 52-week high of 47 cents on Monday. No news stories available today. Great-West Lifeco Inc. (T.GWO) hit a new 52-week high of $40.87 on Monday. No news stories available today. Hydro One Limited (T.H) hit a new 52-week high of $33.15 on Monday.
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
06:15pm, Monday, 30'th Aug 2021
TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the res
Theralase Announces Leadership Transition
04:49pm, Thursday, 19'th Aug 2021
TORONTO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase® ” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
07:00am, Friday, 11'th Jun 2021
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase® ” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the
Theralase Releases Q12021 Interim Financial Statements
06:58pm, Friday, 28'th May 2021
TORONTO, May 28, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the rese
Theralase Release FY2020 Audited Financial Statements
07:00am, Wednesday, 28'th Apr 2021
TORONTO, ON / ACCESSWIRE / April 28, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase(R) Releases Quarterly Newsletter
07:00am, Tuesday, 27'th Apr 2021
TORONTO, ON / ACCESSWIRE / April 27, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and
Theralase Commences Collaborative Research with National Microbiology Laboratory for Development of Coronavirus Vaccine
07:00am, Friday, 09'th Apr 2021
TORONTO, ON / ACCESSWIRE / April 9, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and dev
Theralase Launches Anti-Cancer Therapy Research Centre
07:00am, Monday, 29'th Mar 2021
TORONTO, ON / ACCESSWIRE / March 29, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and de
Theralase Launches Sixth Clinical Study Site in the US for Phase II Bladder Cancer Clinical Study
07:00am, Thursday, 25'th Mar 2021
TORONTO, ON / ACCESSWIRE / March 25, 2021 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and de